Inclusion Criteria:

- Histologically confirmed metastatic medullary or differentiated thyroid cancer.
Diagnosis must be confirmed at University of Wisconsin

- Patients must have measurable disease as defined by RECIST.

- At least 3 weeks from the completion of major surgery, chemotherapy, or other
systemic therapy or local liver therapy to study registration

- No concurrent chemotherapy or radiation therapy

- ECOG Performance Status of ≤ 2

- Ability to provide written informed consent obtained prior to participation in the
study and any related procedures being performed

- Adequate bone marrow, kidney, liver function

- Left ventricular ejection fraction ≥ the lower limit of the institutional normal

- Those with differentiated thyroid cancer must have radioactive iodine resistant
disease, defined by failure to incorporate 131-Iodine after therapy, FDG-avidity on a
PET scan, or progression of measurable disease after 131-Iodine therapy or an allergy
to radioactive iodine

- Hypertension must be well controlled (to less than 150/90 mmHg) on a stable regimen
of anti-hypertensive therapy

Exclusion Criteria:

- Prior HDAC, DAC, HSP90 inhibitors or valproic acid for the treatment of cancer

- Patients who will need valproic acid for any medical condition during the study or
within 5 days prior to first LBH589 treatment

- Impaired cardiac function

- Concomitant use of drugs with a risk of causing torsades de pointes

- Patients with unresolved diarrhea > CTCAE grade 1

- Impairment of gastrointestinal (GI) function or GI disease that may significantly
alter the absorption of oral LBH589

- Other concurrent severe and/or uncontrolled medical conditions

- Women who are pregnant or breast feeding or women of childbearing potential (WOCBP)
not willing to use a double barrier method of contraception during the study and 3
months after last study drug administration. Women of childbearing potential must
have a negative serum pregnancy test within 7 days of the first administration of
oral LBH589.

- Male patients whose sexual partners are WOCBP not using a double method of
contraception during the study and 3 months after the end of treatment

- Patients with a history of another primary malignancy that, in the opinion of the
investigator, would interfere with the assessment of the primary endpoints of the
study

- Patients with known positivity for human immunodeficiency virus (HIV) or hepatitis C

- Patients with any significant history of non-compliance to medical regimens or with
inability to grant a reliable informed consent